Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2007-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.297.15.JPC70004PMID 17387133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

  2006cited by this paper
• The failure of torcetrapib: was it the molecule or the mechanism?

  2006cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions

  2004cited by this paper
• Regulation of reverse cholesterol transport and clinical implications.

  2003cited by this paper
• Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein

  2003cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions

  2003cited by this paper
• Dynamics of reverse cholesterol transport: protection against atherosclerosis.

  2002cited by this paper
• Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.

  2002cited by this paper
• Beyond LDL-C – The Importance of Raising HDL-C

  2002cited by this paper
• HIGH DENSITY LIPOPROTEIN: GUARDIAN OF THE VASCULAR SYSTEM?

  2002cited by this paper
• High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men

  2002cited by this paper
• Effects of plaque composition on vascular remodelling after angioplasty in the MultiVitamins and Probucol (MVP) trial.

  2002cited by this paper
• Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans.

  2001cited by this paper
• High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease

  2001cited by this paper
• American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

  2001cited by this paper
• Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis.

  2001cited by this paper
• Managing the risk of atherosclerosis: the role of high-density lipoprotein.

  2001cited by this paper
• High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

  2000cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• In vitro analysis of coronary atheromatous lesions by intravascular ultrasound; reproducibility and histological correlation of lesion morphology.

  1999cited by this paper
• Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group.

  1999cited by this paper
• In vitro analysis of coronary atheromatous lesions by intravascular ultrasound; reproducibility and histological correlation of lesion morphology.

  1999cited by this paper
• Effects of Probucol on Vascular Remodeling After Coronary Angioplasty

  1999cited by this paper
• Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.

  1997cited by this paper
• Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.

  1997cited by this paper
• Production and Characterization ofa Reconstituted High Density Lipoprotein for Therapeutic Applications

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

  1995cited by this paper
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Prognostic Significance of Progression of Coronary Atherosclerosis

  1993cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper

• HDL and Cardiovascular Disease: Mechanisms, Therapeutic Advances, and Challenges

  2026cites this paper
• Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol

  2026cites this paper
• High-density lipoprotein-based nanoplatforms for macrophage-targeted diagnosis and therapy of atherosclerosis.

  2025cites this paper
• Production, characterization and biodistribution of therapeutic high-density lipoprotein-like nanoparticles reconstituted with or without histidine-tagged recombinant ApoA1.

  2025cites this paper
• Efficacy of Apolipoprotein A-1 Infusion on Coronary Atherosclerosis Postacute Coronary Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.

  2025cites this paper
• Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial.

  2025cites this paper
• Emerging drug delivery strategies for local immunomodulation in atherosclerosis.

  2025cites this paper
• Mechanisms and Applications of Apolipoproteins and Apolipoprotein Mimetic Peptides: Common Pathways in Cardiovascular Disease and Cancer.

  2025cites this paper
• Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization

  2025cites this paper
• HDL-replacement therapy: From traditional to emerging clinical applications

  2025cites this paper
• Radiolabeling lipoproteins to study and manage disease

  2025cites this paper
• Dysfunction of the ABCA1 and ABCG1 Transporters and Their Impact on HDL Metabolism

  2025cites this paper
• The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategies.

  2025cites this paper
• Structural and dynamics of apoA-1 mimetic peptide lipid nanodisc assemblies: A molecular dynamics study.

  2025cites this paper
• Sepsis and high-density lipoproteins: Pathophysiology and potential new therapeutic targets.

  2025cites this paper
• Apolipoprotein A-I Infusions in Coronary Artery Disease: A Systematic Review.

  2025cites this paper
• Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs

  2025cites this paper
• Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?

  2025cites this paper
• High density lipoprotein infusion therapy: A review.

  2024cites this paper
• Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews

  2024cites this paper
• High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction

  2024cites this paper
• Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis.

  2024cites this paper
• Exosome-Mediated Transfer of X-Motif-Tagged Anti-MiR-33a-5p Antagomirs to the Medial Cells of Transduced Rabbit Carotid Arteries

  2024cites this paper
• Evaluation of stenoses using AI video models applied to coronary angiography

  2024cites this paper
• Dysfunctional HDL Diagnostic Metrics for Cardiovascular Disease Risk Stratification: Are we Ready to Implement in Clinics?

  2024cites this paper
• Negatively charged nanodiscs for the reduction of toxicity and enhanced efficacy of polymyxin B against Acinetobacter baumannii sepsis.

  2024cites this paper
• Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?

  2024cites this paper
• New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease

  2024cites this paper
• Mesona chinensis Benth. Extract Ameliorates Hyperlipidemia in High-Fat Diet-Fed Mice and Rats by Regulating the Gut Microbiota

  2024cites this paper
• Can CSL-112 Revolutionize Atherosclerosis Treatment? A Critical Look at the Evidence.

  2024cites this paper
• Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial.

  2024cites this paper
• Enhancing Wound Healing and Anti-Inflammatory Effects by Combination of CIGB-258 and Apolipoprotein A-I against Carboxymethyllysine Toxicity in Zebrafish: Insights into Structural Stabilization and Antioxidant Properties

  2024cites this paper
• Atherosclerotic plaque stabilization and regression: a review of clinical evidence

  2024cites this paper
• Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial

  2024cites this paper
• Enhancing HDL Function to Prevent Atherothrombosis: Is it Time to Efflux the HDL Hypothesis?

  2024cites this paper
• Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents

  2024cites this paper
• Nanomedicine for Diagnosis and Treatment of Atherosclerosis

  2023cites this paper
• HDL as a Treatment Target: Should We Abandon This Idea?

  2023cites this paper
• Mannose-functionalization of reconstituted high-density lipoprotein nanoparticles improves payload delivery and enhances M2-to-M1 phenotype reprogramming of RAW 264.7 macrophages polarized by B16-F10 melanoma cells

  2023cites this paper
• Which Biomarker(s) Augment the Diagnostic Value of the Positive Exercise Electrocardiography Test: Systemic Inflammatory Index, Plasma Atherogenic Index, or Monocyte/HDL-C Ratio?

  2023cites this paper
• Seed-Specific Expression of Apolipoprotein A-IMilano Dimer in Engineered Rice Lines

  2023cites this paper
• Mannose-Coated Reconstituted Lipoprotein Nanoparticles for the Targeting of Tumor-Associated Macrophages: Optimization, Characterization, and In Vitro Evaluation of Effectiveness

  2023cites this paper
• Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease.

  2023cites this paper
• Seed-Specific Expression of Apolipoprotein A-I Milano Dimer in Rice Engineered Lines

  2023cites this paper
• BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis

  2023cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of CSL112

  2023cites this paper
• Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction

  2023cites this paper
• Prognostic Value of Different Levels of Uric Acid in Patients with Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention

  2023cites this paper
• High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities

  2023cites this paper
• Assessing the relationship between monocyte to HDL cholesterol ratio and mortality in patients with hypertrophic cardiomyopathy.

  2023cites this paper
• A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

  2023cites this paper
• HDL abnormalities in type 2 diabetes: Clinical implications.

  2023cites this paper
• Very low HDL levels: clinical assessment and management

  2023cites this paper
• CathAI: fully automated coronary angiography interpretation and stenosis estimation

  2023cites this paper
• HDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis.

  2023cites this paper
• Targeting Epsins by nanotherapy regulates lipid metabolism and promotes ABCG1-mediated cholesterol efflux to fortify atheroma regression

  2022cites this paper
• Oxidative modification of HDL by lipid aldehydes impacts HDL function.

  2022cites this paper
• High-density lipoproteins: from quantitative measures to functional assessment and therapy (review of literature).

  2022cites this paper
• Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies

  2022cites this paper
• Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration.

  2022cites this paper
• High-density lipoprotein revisited: biological functions and clinical relevance

  2022cites this paper
• HDL and Therapy.

  2022cites this paper
• Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.

  2022cites this paper
• Autophagy Is Differentially Regulated in Leukocyte and Nonleukocyte Foam Cells During Atherosclerosis

  2022cites this paper
• The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy

  2022cites this paper
• Replenishing HDL with synthetic HDL has multiple protective effects against sepsis in mice

  2022cites this paper
• Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

  2022cites this paper
• HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?

  2022cites this paper
• Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model.

  2022cites this paper
• An ApoA-I Mimic Peptide of 4F Promotes SDF-1α Expression in Endothelial Cells Through PI3K/Akt/ERK/HIF-1α Signaling Pathway

  2022cites this paper
• The Role of High-Density Lipoprotein Cholesterol in 2022

  2022cites this paper
• ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

  2022cites this paper
• Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review.

  2022cites this paper
• Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention

  2022cites this paper
• Epsin Nanotherapy Regulates Cholesterol Transport to Fortify Atheroma Regression

  2022cites this paper
• Addressing dyslipidemic risk beyond LDL-cholesterol

  2022cites this paper
• HDL and Endothelial Function.

  2022cites this paper
• End‐diastolic segmentation of intravascular ultrasound images enables more reproducible volumetric analysis of atheroma burden

  2021cites this paper
• HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role

  2021cites this paper
• Apolipoprotein A-I Mimetics for Treatment of the Residual Risk of Cardiovascular Disease

  2021cites this paper
• Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases.

  2021cites this paper
• Immune-based therapies in cardiovascular and metabolic diseases: past, present and future

  2021cites this paper
• White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study

  2021cites this paper
• Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis

  2021cites this paper
• HDL and type 2 diabetes: the chicken or the egg?

  2021cites this paper
• Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications

  2021cites this paper
• High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

  2021cites this paper
• Co-administration of CSL112 (apolipoprotein A-I [human]) with atorvastatin and alirocumab is not associated with increased hepatotoxic or toxicokinetic effects in rats.

  2021cites this paper
• (r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?

  2021cites this paper
• HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases

  2021cites this paper
• Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases

  2021cites this paper
• High-density lipoproteins, reverse cholesterol transport and atherogenesis

  2021cites this paper
• Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial

  2021cites this paper
• Structure of Lipoproteins and Their Capacity for Lipid Exchange: Relevance for Development of Atherosclerosis and Its Treatment by HDL Therapy

  2021cites this paper
• Peptide-based high-density lipoprotein promotes adipose tissue browning and restrains development of atherosclerosis and type 2 diabetes

  2021cites this paper
• High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?

  2021cites this paper
• ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis.

  2021cites this paper
• Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation

  2021cites this paper
• Role of monocyte to high-density lipoprotein cholesterol ratio in predicting left atrial enlargement in hypertensive patients.

  2021cites this paper
• Is a High HDL-Cholesterol Level Always Beneficial?

  2021cites this paper